Minerva Neurosciences, Inc. (NERV)

Market Cap	295.06M +2,511.1%
Revenue (ttm)	n/a
Net Income	-293.42M
EPS	-34.67
Shares Out	43.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	264,746
Open	6.43
Previous Close	6.29
Day's Range	6.25 - 6.75
52-Week Range	1.30 - 12.46
Beta	-0.21
Analysts	Buy
Price Target	10.50 (+56.02%)
Earnings Date	May 12, 2026

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2014
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: NERV
• Website: https://www.minervaneurosciences.com

Analyst Summary

According to 2 analysts, the average rating for NERV stock is "Buy." The 12-month stock price target is $10.5, which is an increase of 56.02% from the latest price.

Price Target

$10.5

(56.02% upside)

Analyst Consensus: Buy